Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

Linxi Zeng; Sen Feng; Lulu Yao; Bin Wang; Guoqiang Zhang

doi:10.5114/ada.2023.133959

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2023
vol. 40

Send email

Copy url:

abstract:

Review paper

Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

Linxi Zeng

¹

,

Sen Feng

¹

,

Lulu Yao

¹

,

Bin Wang

¹

,

Guoqiang Zhang

^{1, 2}

Department of Dermatology, The First Hospital of Hebei Medical University, Yuhua District, Shijiazhuang City, Hebei Province, China
Candidate Branch of National Clinical Research Center for Skin Diseases, Shijiazhuang, China

Adv Dermatol Allergol 2023; XL (6): 734-740

DOI: https://doi.org/10.5114/ada.2023.133959

Online publish date: 2024/01/08

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Zeng L, Feng S, Yao L, Wang B, Zhang G. Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(6):734-740. doi:10.5114/ada.2023.133959.

APA

Zeng, L., Feng, S., Yao, L., Wang, B.,  & Zhang, G. (2023). Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(6), 734-740. https://doi.org/10.5114/ada.2023.133959

Chicago

Zeng, Linxi, Sen Feng, Lulu Yao, Bin Wang,  and Guoqiang Zhang. 2023. "Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials". Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii 40 (6): 734-740. doi:10.5114/ada.2023.133959.

Harvard

Zeng, L., Feng, S., Yao, L., Wang, B.,  and Zhang, G. (2023). Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, 40(6), pp.734-740. https://doi.org/10.5114/ada.2023.133959

MLA

Zeng, Linxi et al. "Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials." Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii, vol. 40, no. 6, 2023, pp. 734-740. doi:10.5114/ada.2023.133959.

Vancouver

Zeng L, Feng S, Yao L, Wang B, Zhang G. Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2023;40(6):734-740. doi:10.5114/ada.2023.133959.

Introduction:
Recent studies have confirmed the possibility of using upadacitinib for treating atopic dermatitis (AD). However, there is no meta-analysis to summarize and quantify the efficacy and safety of the drug, especially for adolescents with AD.

Aim:
To evaluate the overall efficacy and safety of upadacitinib in adults and adolescents with AD.

Material and methods:
We developed this systematic review and meta-analysis according to PRISMA guidelines. Risk-of-bias assessment tool, RoB2 (revised version 2019) was used for quality assessment.

Results:
Four RCTs were enrolled in the analysis, 3 of which on both adults and adolescents, while the other on adults only. For either adults or adolescents, the group treated with upadacitinib all had better performance than controls: EASI-75 (adults): RR = 4.68, 95% CI: 4.09, 5.35; NRS4 (adults): RR = 4.07, 95% CI: 3.15, 5.25; EASI-75 (adolescents): RR = 4.16, 95% CI: 2.70, 6.42; NRS4 (adolescents): RR = 4.52, 95% CI: 2.49, 8.21. Furthermore, upadacitinib 30 mg was more effective than 15 mg. For serious AEs, upper respiratory tract infection and headache, there was no significant difference between the upadacitinib group and controls. However, the treatment of upadacitinib may increase the risk of nasopharyngitis, increase blood creatine phosphokinase and cause acne.

Conclusions:
Upadacitinib seems to be a promising drug for AD. More long-term and larger-sized randomized clinical trials are required to further assess the safety and efficacy of upadacitinib for AD.

keywords:

Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials

Linxi Zeng 1 , Sen Feng 1 , Lulu Yao 1 , Bin Wang 1 , Guoqiang Zhang 1, 2

atopic dermatitis, JAK inhibitors, upadacitinib, meta-analysis

Linxi Zeng

¹

,

Sen Feng

¹

,

Lulu Yao

¹

,

Bin Wang

¹

,

Guoqiang Zhang

^{1, 2}